logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Graft Rejection

    FiltersReset Filters
    10 results

    • everolimus

      (Everolimus)
      Ascend Laboratories, LLC
      Usage: Everolimus tablets are indicated for the prevention of organ rejection in adult kidney transplant patients at low to moderate immunologic risk and in liver transplant patients, administered with specific immunosuppressants. Therapeutic drug monitoring is recommended. Safety has not been established for high-risk kidney recipients or in pediatric patients.

    • mycophenolic acid

      (Mycophenolic Acid)
      Accord Healthcare Inc.
      Usage: Mycophenolic acid delayed release tablets are indicated for preventing organ rejection in adult and pediatric kidney transplant patients, used alongside cyclosporine and corticosteroids. They should not be interchanged with mycophenolate mofetil without medical supervision due to differing absorption rates.

    • mycophenolic acid

      (mycophenolic acid)
      CONCORD BIOTECH LIMITED
      Usage: Mycophenolic acid delayed-release tablets are indicated for preventing organ rejection in kidney transplant patients aged 5 and older, used alongside cyclosporine and corticosteroids. It is not interchangeable with mycophenolate mofetil without physician supervision due to differing absorption rates.

    • mycophenolic acid

      (Mycophenolic Acid)
      Biocon Pharma Inc.
      Usage: Mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in adult and pediatric kidney transplant patients (5 years and older). They should be used alongside cyclosporine and corticosteroids, and not interchangeably with mycophenolate mofetil products without physician supervision.

    • mycophenolic acid

      (MYCOPHENOLIC ACID)
      Ascend Laboratories, LLC
      Usage: Mycophenolic acid delayed-release tablets are indicated for preventing organ rejection in kidney transplant patients, both adults and pediatric patients aged 5 and older, in combination with cyclosporine and corticosteroids. Interchangeability with mycophenolate mofetil is not recommended without physician supervision due to absorption differences.

    • prednisolone sodium phosphate

      (Prednisolone Sodium Phosphate)
      PAI Holdings, LLC
      Usage: Prednisolone sodium phosphate oral solution is indicated for severe allergic conditions, dermatologic and endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, acute multiple sclerosis exacerbations, ocular inflammation, respiratory diseases, rheumatic disorders, and specific miscellaneous conditions involving tuberculosis and organ rejection.

    • prograf

      (Tacrolimus)
      Astellas Pharma US, Inc.
      Usage: PROGRAF® is indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic transplants of the kidney, liver, heart, or lung, as part of a regimen with other immunosuppressants.

    • sirolimus

      (Sirolimus)
      Ascend Laboratories, LLC
      Usage: Sirolimus is indicated for the prophylaxis of organ rejection in renal transplant patients aged 13 and older, particularly in high-risk groups, and for the treatment of lymphangioleiomyomatosis (LAM). Its use involves specific combinations with cyclosporine and corticosteroids based on immunologic risk levels.

    • sirolimus

      (sirolimus)
      NorthStar RxLLC
      Usage: Sirolimus tablets are indicated for the prophylaxis of organ rejection in renal transplant patients aged 13 and older and for treating lymphangioleiomyomatosis (LAM). In renal transplantation, dosing varies based on immunologic risk, with specific recommendations for combining with cyclosporine and corticosteroids.

    • zortress

      (everolimus)
      Novartis Pharmaceuticals Corporation
      Usage: Zortress is indicated for the prophylaxis of organ rejection in adult kidney and liver transplant patients at low to moderate immunologic risk. It is used in combination with other immunosuppressants and corticosteroids, with recommended therapeutic drug monitoring for efficacy. Safety in certain populations is not established.